ZA201408955B - Anti-blys antibody - Google Patents

Anti-blys antibody

Info

Publication number
ZA201408955B
ZA201408955B ZA2014/08955A ZA201408955A ZA201408955B ZA 201408955 B ZA201408955 B ZA 201408955B ZA 2014/08955 A ZA2014/08955 A ZA 2014/08955A ZA 201408955 A ZA201408955 A ZA 201408955A ZA 201408955 B ZA201408955 B ZA 201408955B
Authority
ZA
South Africa
Prior art keywords
blys antibody
blys
antibody
Prior art date
Application number
ZA2014/08955A
Other languages
English (en)
Inventor
Hongbing Shu
Hui Feng
Bo Chen
Original Assignee
Shanghai Union Biopharm Co Ltd
Wuhan Therasource Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Union Biopharm Co Ltd, Wuhan Therasource Biosciences Inc filed Critical Shanghai Union Biopharm Co Ltd
Publication of ZA201408955B publication Critical patent/ZA201408955B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ZA2014/08955A 2012-05-22 2014-12-05 Anti-blys antibody ZA201408955B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201210160474.3A CN103421113B (zh) 2012-05-22 2012-05-22 抗BLyS抗体
PCT/CN2013/076074 WO2013174264A1 (zh) 2012-05-22 2013-05-22 抗BLyS抗体

Publications (1)

Publication Number Publication Date
ZA201408955B true ZA201408955B (en) 2015-12-23

Family

ID=49623127

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2014/08955A ZA201408955B (en) 2012-05-22 2014-12-05 Anti-blys antibody

Country Status (8)

Country Link
US (1) US9828423B2 (enExample)
EP (2) EP2853543B1 (enExample)
JP (1) JP6006404B2 (enExample)
CN (1) CN103421113B (enExample)
IN (1) IN2014MN02367A (enExample)
RU (1) RU2613422C2 (enExample)
WO (1) WO2013174264A1 (enExample)
ZA (1) ZA201408955B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0615672D0 (en) 2006-08-07 2006-09-13 Rencol Tolerance Rings Ltd Assembly of a shaft and a housing assembly
ES2702315T3 (es) 2012-08-24 2019-02-28 Univ California Anticuerpos y vacunas para su uso en tratar cánceres ROR1 e inhibir metástasis
CN104045713B (zh) * 2013-03-13 2019-02-12 江苏诺迈博生物医药科技有限公司 一种抗Blys的单克隆抗体及含有该抗体的药物组合物
CN104804092B (zh) * 2014-01-29 2018-03-27 天津胜发生物技术有限公司 一种抗b细胞生长刺激因子的纳米抗体及其用途
CN104804090B (zh) * 2014-01-29 2018-03-27 普瑞金（深圳）生物技术有限公司 一种抗b细胞生长刺激因子的纳米抗体和用途
CN104804091B (zh) * 2014-01-29 2018-03-27 普瑞金（深圳）生物技术有限公司 一种抗b细胞生长刺激因子的纳米抗体及用途
EP3151857A4 (en) * 2014-06-03 2018-04-18 Merck Sharp & Dohme Corp. Anti-blys antibodies
CN104628856A (zh) * 2015-01-23 2015-05-20 中国人民解放军军事医学科学院放射与辐射医学研究所 一种抗BLyS单链抗体及其制备方法和用途
CN105061596B (zh) * 2015-08-05 2019-01-29 江苏诺迈博生物医药科技有限公司 人b淋巴细胞刺激因子的单克隆抗体及其应用
CN106916224B (zh) * 2015-12-28 2021-03-23 中国人民解放军军事医学科学院放射与辐射医学研究所 抗b淋巴细胞刺激因子单克隆抗体及其制备方法和用途
MX2018016330A (es) 2016-06-27 2020-02-17 Univ California Combinaciones para tratamiento del cáncer.
WO2018006824A1 (zh) * 2016-07-06 2018-01-11 上海开拓者生物医药有限公司 一种BLyS抗体及其制备方法和应用
CA3092434A1 (en) * 2017-02-27 2018-08-30 Caerus Therapeutics, Inc. Compositions of a novel anti-human ceacam6 antibody and uses thereof
WO2020160199A1 (en) * 2019-01-31 2020-08-06 Siemens Healthcare Diagnostics Inc. Anti-naloxone and anti-naltrexone monoclonal antibodies and methods of production and use thereof
CN112111461B (zh) * 2020-08-17 2022-08-30 浙江正熙生物医药有限公司 一种单细胞分选构建单克隆抗体高产株细胞工作库的方法
WO2022223028A1 (zh) * 2021-04-23 2022-10-27 上海君实生物医药科技股份有限公司 抗BLyS抗体、其药物组合物及其用途
JP2025533898A (ja) * 2022-10-07 2025-10-09 アブウィズ バイオ，インコーポレイテッド 抗ｉｇｅ抗体
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0939804B2 (en) * 1996-10-25 2011-06-15 Human Genome Sciences, Inc. NEUTROKINE alpha
US6812327B1 (en) * 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
MXPA02012434A (es) 2000-06-16 2004-09-06 Cambridge Antibody Tech Anticuerpos que se unen inmunoespecificamente a estimulador de linfocitos ii.
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
WO2003055979A2 (en) 2001-11-16 2003-07-10 Human Genome Sciences, Inc. ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS
US20020150579A1 (en) * 2002-01-10 2002-10-17 Kimberly Robert P. B lymphocyte stimulator (BLyS) as a marker in management of systemic lupus erythematosus
CN1168831C (zh) 2002-05-24 2004-09-29 张志方 一种重组人b淋巴细胞刺激因子表达载体的构建、dna免疫制备单克隆抗体及其应用
RU2005141541A (ru) * 2003-06-05 2006-06-27 Дженентек, Инк. (Us) Комбинированная терапия в-клеточных нарушений
MXPA06004301A (es) * 2003-10-20 2006-06-05 Biogen Idec Inc Regimenes terapeuticos para antagonistas del factor de activacion de celulas b.
CN101851291B (zh) * 2010-02-09 2011-10-26 中国人民解放军第四军医大学 一种抗人baff单克隆抗体的重链和轻链可变区

Also Published As

Publication number Publication date
WO2013174264A1 (zh) 2013-11-28
RU2014133410A (ru) 2016-07-10
US20150259409A1 (en) 2015-09-17
EP3792280A2 (en) 2021-03-17
CN103421113B (zh) 2018-01-19
RU2613422C2 (ru) 2017-03-16
CN103421113A (zh) 2013-12-04
EP3792280A3 (en) 2021-07-21
IN2014MN02367A (enExample) 2015-08-14
JP2015517505A (ja) 2015-06-22
JP6006404B2 (ja) 2016-10-12
EP2853543A8 (en) 2015-05-13
EP2853543A1 (en) 2015-04-01
EP2853543B1 (en) 2020-09-02
EP2853543A4 (en) 2016-03-30
US9828423B2 (en) 2017-11-28
BR112014025651A2 (pt) 2017-07-04

Similar Documents

Publication Publication Date Title
IL264558A (en) Anti–il–23p19 antibodies
ZA201407509B (en) Anti-fcrn antibodies
ZA201408955B (en) Anti-blys antibody
ZA201407897B (en) Protease-regulated antibodies
ZA201409358B (en) Anti-siglec- 15 antibodies
ZA201407316B (en) Anti-fgfr2 antibody
SG11201504765VA (en) Anti-h7cr antibodies
ZA201407079B (en) Cdr-modified anti-siglec-15 antibody
EP2920142A4 (en) MÉTHANOFULLERRÈNES
GB201220242D0 (en) Antibody
EP2811018A4 (en) ANTI-BODY ANTI-sAPPß
IL235188A0 (en) Antibodies against c-pdgf
GB201215711D0 (en) Higher
AU345893S (en) Treehouse
GB201211593D0 (en) Gyro-twig
GB201201668D0 (en) LOCnlatch
GB201201023D0 (en) Sharkbitze
GB201200644D0 (en) Visualiser
GB201200605D0 (en) Buttermesh
GB201200226D0 (en) Kinibra
GB201200207D0 (en) CondText
GB201200011D0 (en) Eggboiler